WINNIPEG, Jan. 13 /CNW/ - (TSX: IM) -- IMRIS Inc. ("IMRIS" or the "Company") today announced the sale of IMRISneuro to CEA-LETI for CLINATEC(R) in Grenoble, France.
Within CEA-LETI, CLINATEC(R) is a biomedical research initiative in partnership with Grenoble University Hospital (CHU) dedicated to advancing micro nanotechnologies in support of developing therapeutic solutions for cerebral and neuro-degenerative disorders such as Parkinson's disease and Alzheimer's disease. CEA-LETI's CLINATEC(R) will become the first location in all of Europe with the unique capabilities of IMRISneuro and will use the system in conjunction with its deep brain stimulation and brain computer interface clinical studies.
The IMRISneuro suite will feature a wide bore 1.5T MRI that will move between an operating theatre and a diagnostic facility, providing state-of-the-art, multi-functional capabilities. With the IMRISneuro system within CLINATEC(R) platform, researchers will have access to high resolution MR images on demand - before, during and after procedures without moving the patient.
Designed specifically for neurosurgery, IMRISneuro provides clinicians with timely images during procedures to assist them in making better decisions for improved patient outcomes. IMRISneuro does not require the patient to be transported for scanning, so the optimum patient positioning is never compromised. Clinical workflow and access to the patient is not impacted and the magnet is removed completely from the operating room when scanning is complete. No other system offers the same degree of safety for both the patient and the surgical environment.
"Today's announcement is an important milestone in our continuing efforts to expand the applications for IMRISneuro and to extend the benefits of our systems to medical facilities around the world," said David Graves, IMRIS CEO. "We are pleased to formally mark our entry into Europe with CEA CLINATEC(R) and to see the benefits of our system contribute to the important innovative research work they have underway."
IMRIS (TSX: IM) is a global leader in providing image guided therapy solutions. These solutions feature fully integrated surgical and interventional suites that incorporate magnetic resonance, fluoroscopy and computed tomography to deliver on demand imaging during procedures. The Company's systems serve the neurosurgical, cardiovascular and neurovascular markets and have been selected by leading medical institutions around the world.
About CEA-LETI and CLINATEC(R)
CEA is a French research and technology organisation, with activities in three main areas: low carbon energies, technologies for information and healthcare, and defence and security. Within CEA, CEA-LETI (Laboratory for Electronics & Information Technology) works with companies in order to increase their competitiveness through technological innovation and transfers. LETI is focused on micro and nanotechnologies and their applications, from wireless devices and systems, to biology and healthcare or photonics. Nanoelectronics and microsystems (MEMS) are at the core of its activities. As a major player in MINATEC excellence centre, Leti operates 8,000-m(2) state-of-the-art clean rooms, on 24/7 mode, on 200mm and 300mm wafer standards. With 1,200 employees, Leti trains more than 150 Ph.D. students and hosts 200 assignees from partner companies. Strongly committed to the creation of value for the industry, Leti puts a strong emphasis on intellectual property and owns more than 1,400 patent families. Together with Grenoble University Hospital (CHU), and Joseph Fourier University, CEA-LETI has launched CLINATEC(R), a unique biomedical research initiative. As a pioneering infrastructure, CLINATEC(R) features a unique gathering of micronanotechnology lab, in vitro and in vivo biology and animal research and will include around the IMRISneuro an operating room equipped with a robotized microscope, a robotized stereotactic arm and bidirectional Xrays, associated to a set of six bedrooms, and other functional imaging modalities such as MEG, and SPECT-CT. For more information, visit www.leti.fr.
SOURCE IMRIS Inc.
For further information: For further information: Brad Woods, Director Investor Relations & Corporate Communications, IMRIS Inc., Tel: (204) 480-7094, Email: firstname.lastname@example.org